Atlas Venture

Founded 1980
Founders Michiel de Haan


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 488
Average round size
The average size of a deal this fund participated in
Portfolio companies 288
Rounds per year 11.90
Lead investments 70
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 146
Key employees 6
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Software
  • Therapeutics
  • Medical

Atlas Venture is the famous VC, which was founded in 1980. The leading representative office of defined VC is situated in the Cambridge. The fund was located in North America if to be more exact in United States.

The fund was created by Michiel de Haan. Besides them, we counted 6 critical employees of this fund in our database.

The average startup value when the investment from Atlas Venture is 10-50 millions dollars. Considering the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2014. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Atlas Venture works on 3 percentage points less the average amount of lead investments. The higher amount of exits for fund were in 2014. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 13-24 investment rounds annually.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Atlas Venture, startups are often financed by Techstars Boston Accelerator, Highland Capital Partners, Bessemer Venture Partners. The meaningful sponsors for the fund in investment in the same round are Sofinnova Investments, Partners Innovation Fund, Flagship Pioneering. In the next rounds fund is usually obtained by Venrock, Silicon Valley Bank, SV Health Investors.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular fund investment industries, there are Software, Medical. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Isilon Systems, DraftKings, Carbon Black

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Disc Medicine

Health Care
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Versanis Bio

Life Science
$70M31 Aug 2021 Oakland, California, United States

Vigil Neuroscience

$90M18 Aug 2021 Cambridge, Massachusetts, United States

Nimbus Therapeutics

Alternative Medicine
Health Care
$105M13 Jul 2021 Cambridge, Massachusetts, United States

Vedere Bio

Health Care
$77M18 May 2021 Cambridge, Massachusetts, United States

Xilio Therapeutics

Health Care
Health Diagnostics
$95M24 Feb 2021 Massachusetts, United States

Day One Biopharmaceuticals

Health Care
$130M10 Feb 2021 South San Francisco, California, United States

Gemini Therapeutics

Health Diagnostics
$95M08 Feb 2021 Cambridge, Massachusetts, United States

Scorpion Therapeutics

Health Care
Life Science
$162M07 Jan 2021 Boston, Massachusetts, United States
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

Disc Medicine Raises $90M in Series B Funding

– Disc Medicine from Cambridge MA develops therapeutic candidates for hematology.
– Series B $90M round was led by OrbiMed and attracted new investor – Arix Bioscience as well as existing investors Atlas Venture, Novo Holdings and Access Biotechnology.
– The new investment will be aimed at developing the company’s hematology pipeline of therapeutic candidates.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Atlas Venture?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: